{
    "root": "4583ae02-09cb-4dd4-b5e7-b3074f3b95aa",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Lurasidone hydrochloride",
    "value": "20250321",
    "ingredients": [
        {
            "name": "LURASIDONE HYDROCHLORIDE",
            "code": "O0P4I5851I"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "CITRIC ACID MONOHYDRATE",
            "code": "2968PHW8QP"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POLOXAMER 407",
            "code": "TUF2IVW3M2"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        }
    ],
    "indications": "lurasidone hydrochloride indicated : treatment adult adolescent patients ( 13 17 years ) schizophrenia [ ( 14.1 ) ] . monotherapy treatment adult pediatric patients ( 10 17 years ) major depressive episode associated bipolar disorder ( bipolar depression ) [ ( 14.2 ) ] . adjunctive treatment lithium valproate adult patients major depressive episode associated bipolar disorder ( bipolar depression ) [ ( 14.2 ) ] .",
    "contraindications": "lurasidone hydrochloride tablets taken food ( least 350 calories ) . food substantially increases absorption lurasidone hydrochloride ( 2.3 , 12.3 ) . indication starting dose recommended dose schizophrenia–adults ( 2.1 ) 40 mg per day 40 mg 160 mg per day schizophrenia – adolescents ( 13 17 years ) ( 2.1 ) 40 mg per day 40 mg 80 mg per day bipolar depression–adults ( 2.2 ) 20 mg per day 20 mg 120 mg per day bipolar depression – pediatric patients ( 10 17 years ) ( 2.2 ) 20 mg per day 20 mg 80 mg per day moderate severe renal impairment : recommended starting dose 20 mg per day , maximum recommended dose 80 mg per day ( 2.4 , 8.6 ) . moderate severe hepatic impairment : recommended starting dose 20 mg per day . maximum recommended dose 80 mg per day moderate hepatic impairment 40 mg per day severe hepatic impairment ( 2.5 , 8.7 ) . concomitant moderate cyp3a4 inhibitor ( e.g . , diltiazem ) : lurasidone hydrochloride tablets dose reduced half original dose level . recommended starting dose 20 mg per day . maximum recommended dose 80 mg per day ( 2.6 , 7.1 ) concomitant moderate cyp3a4 inducer : may necessary increase dose lurasidone hydrochloride tablets ( 2.6 , 7.1 )",
    "warningsAndPrecautions": "20 mg lurasidone hydrochloride tablets yellow light yellow , round shaped , coated tablets , debossed `` c31 `` one side plain side supplied : ndc 68382-965-06 bottle 30 tablets child-resistant closure ndc 68382-965-16 bottle 90 tablets child-resistant closure ndc 68382-965-01 bottle 100 tablets ndc 68382-965-05 bottle 500 tablets ndc 68382-965-77 cartons 100 tablets ( 10 x 10 unit-dose ) 40 mg lurasidone hydrochloride tablets white white , round shaped , coated tablets , debossed `` c32 `` one side plain side supplied : ndc 68382-966-06 bottle 30 tablets child-resistant closure ndc 68382-966-16 bottle 90 tablets child-resistant closure ndc 68382-966-01 bottle 100 tablets ndc 68382-966-05 bottle 500 tablets ndc 68382-966-77 cartons 100 tablets ( 10 x 10 unit-dose ) 60 mg lurasidone hydrochloride tablets white white , modified capsule shaped , coated tablets , debossed `` c33 `` one side plain side supplied : ndc 68382-859-06 bottle 30 tablets child-resistant closure ndc 68382-859-16 bottle 90 tablets child-resistant closure ndc 68382-859-01 bottle 100 tablets ndc 68382-859-05 bottle 500 tablets ndc 68382-859-77 cartons 100 tablets ( 10 x 10 unit-dose ) 80 mg lurasidone hydrochloride tablets yellow light yellow , oval shaped , coated tablets , debossed `` c34 `` one side plain side supplied : ndc 68382-967-06 bottle 30 tablets child-resistant closure ndc 68382-967-16 bottle 90 tablets child-resistant closure ndc 68382-967-01 bottle 100 tablets ndc 68382-967-05 bottle 500 tablets ndc 68382-967-77 cartons 100 tablets ( 10 x 10 unit-dose ) 120 mg lurasidone hydrochloride tablets white white , oval shaped , coated tablets , debossed `` c35 `` one side plain side supplied : ndc 68382-968-06 bottle 30 tablets child-resistant closure ndc 68382-968-16 bottle 90 tablets child-resistant closure ndc 68382-968-01 bottle 100 tablets ndc 68382-968-05 bottle 500 tablets ndc 68382-968-77 cartons 100 tablets ( 10 x 10 unit-dose ) storage store lurasidone hydrochloride tablets 20°c 25°c ( 68°f 77°f ) [ usp controlled room temperature ] .",
    "adverseReactions": "known hypersensitivity lurasidone hydrochloride components formulation ( 4 ) . concomitant strong cyp3a4 inhibitor ( e.g . , ketoconazole ) ( 2.6 , 4 , 7.1 ) . concomitant strong cyp3a4 inducer ( e.g . , rifampin ) ( 2.6 , 4 , 7.1 ) .",
    "indications_original": "Lurasidone hydrochloride is indicated for: \n                  \n                     Treatment of adult and adolescent patients (13 to 17 years) with schizophrenia [see Clinical Studies (14.1)].\n                     Monotherapy treatment of adult and pediatric patients (10 to 17 years) with major depressive episode associated with bipolar I disorder (bipolar depression) [see Clinical Studies (14.2)].\n                     Adjunctive treatment with lithium or valproate in adult patients with major depressive episode associated with bipolar I disorder (bipolar depression) [see Clinical Studies (14.2)].",
    "contraindications_original": "Lurasidone hydrochloride tablets should be taken with food (at least 350 calories). Administration with food substantially increases the absorption of lurasidone hydrochloride ( 2.3 , 12.3 ). Indication Starting Dose Recommended Dose Schizophrenia–adults ( 2.1 ) 40 mg per day 40 mg to 160 mg per day Schizophrenia – adolescents (13 to 17 years) ( 2.1 ) 40 mg per day 40 mg to 80 mg per day Bipolar Depression–adults ( 2.2 ) 20 mg per day 20 mg to 120 mg per day Bipolar Depression – pediatric patients (10 to 17 years) ( 2.2 ) 20 mg per day 20 mg to 80 mg per day Moderate and Severe Renal Impairment: Recommended starting dose is 20 mg per day, and the maximum recommended dose is 80 mg per day ( 2.4 , 8.6 ). Moderate and Severe Hepatic Impairment: Recommended starting dose is 20 mg per day. The maximum recommended dose is 80 mg per day in moderate hepatic impairment and 40 mg per day in severe hepatic impairment ( 2.5 , 8.7 ). Concomitant Use of a Moderate CYP3A4 inhibitor (e.g., diltiazem): Lurasidone hydrochloride tablets dose should be reduced to half of the original dose level. Recommended starting dose is 20 mg per day. Maximum recommended dose is 80 mg per day ( 2.6 , 7.1 ) Concomitant Use of a Moderate CYP3A4 Inducer: It may be necessary to increase the dose of lurasidone hydrochloride tablets ( 2.6 , 7.1 )",
    "warningsAndPrecautions_original": "20 mg lurasidone hydrochloride tablets are yellow to light yellow, round shaped, coated tablets, debossed with \"C31\" on one side and plain on the other side and are supplied as:\n                  NDC 68382-965-06 in bottle of 30 tablets with child-resistant closure\n                  NDC 68382-965-16 in bottle of 90 tablets with child-resistant closure\n                  NDC 68382-965-01 in bottle of 100 tablets\n                  NDC 68382-965-05 in bottle of 500 tablets \n                  NDC 68382-965-77 in cartons of 100 tablets (10 x 10 unit-dose) \n                  40 mg lurasidone hydrochloride tablets are white to off white, round shaped, coated tablets, debossed with \"C32\" on one side and plain on the other side and are supplied as:\n                  NDC 68382-966-06 in bottle of 30 tablets with child-resistant closure\n                  NDC 68382-966-16 in bottle of 90 tablets with child-resistant closure\n                  NDC 68382-966-01 in bottle of 100 tablets\n                  NDC 68382-966-05 in bottle of 500 tablets \n                  NDC 68382-966-77 in cartons of 100 tablets (10 x 10 unit-dose) \n                  60 mg lurasidone hydrochloride tablets are white to off white, modified capsule shaped, coated tablets, debossed with \"C33\" on one side and plain on the other side and are supplied as:\n                  NDC 68382-859-06 in bottle of 30 tablets with child-resistant closure\n                  NDC 68382-859-16 in bottle of 90 tablets with child-resistant closure\n                  NDC 68382-859-01 in bottle of 100 tablets\n                  NDC 68382-859-05 in bottle of 500 tablets \n                  NDC 68382-859-77 in cartons of 100 tablets (10 x 10 unit-dose) \n                  80 mg lurasidone hydrochloride tablets are yellow to light yellow, oval shaped, coated tablets, debossed with \"C34\" on one side and plain on the other side and are supplied as:\n                  NDC 68382-967-06 in bottle of 30 tablets with child-resistant closure\n                  NDC 68382-967-16 in bottle of 90 tablets with child-resistant closure\n                  NDC 68382-967-01 in bottle of 100 tablets\n                  NDC 68382-967-05 in bottle of 500 tablets \n                  NDC 68382-967-77 in cartons of 100 tablets (10 x 10 unit-dose) \n                  120 mg lurasidone hydrochloride tablets are white to off white, oval shaped, coated tablets, debossed with \"C35\" on one side and plain on the other side and are supplied as:\n                  NDC 68382-968-06 in bottle of 30 tablets with child-resistant closure\n                  NDC 68382-968-16 in bottle of 90 tablets with child-resistant closure\n                  NDC 68382-968-01 in bottle of 100 tablets\n                  NDC 68382-968-05 in bottle of 500 tablets \n                  NDC 68382-968-77 in cartons of 100 tablets (10 x 10 unit-dose) \n                  \n                     \n                        Storage\n                     \n                  \n                  Store lurasidone hydrochloride tablets at 20°C to 25°C (68°F to 77°F) [See USP Controlled Room Temperature].",
    "adverseReactions_original": "Known hypersensitivity to lurasidone hydrochloride or any components in the formulation ( 4 ). Concomitant use with a strong CYP3A4 inhibitor (e.g., ketoconazole) ( 2.6 , 4 , 7.1 ). Concomitant use with a strong CYP3A4 inducer (e.g., rifampin) ( 2.6 , 4 , 7.1 )."
}